We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

6 hedge funds and large institutions have $1.01M invested in Pacer BioThreat Strategy ETF in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 4 → 6 (+2)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

10% less capital invested

Capital invested by funds: $1.12M → $1.01M (-$112K)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$38.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$28.2K
3
UBS Group
UBS Group
Switzerland
+$913
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$28

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$308K
2
Osaic Holdings
Osaic Holdings
Arizona
-$1.96K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$384K +$28.2K +1,021 +8%
Osaic Holdings
2
Osaic Holdings
Arizona
$380K -$1.96K -71 -0.5%
UBS Group
3
UBS Group
Switzerland
$131K +$913 +33 +0.7%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$73K -$308K -11,119 -81%
Rockefeller Capital Management
5
Rockefeller Capital Management
New York
$39K +$38.8K +1,403 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$28 +$28 +1 New

VIRS Hedge Fund Activity: Q4 2022 in Review

6 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q4 2022, worth a combined $1.01M — down 10% from $1.12M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VIRS positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $38.8K. The largest seller was Royal Bank of Canada, cutting an estimated $308K.

  • 6 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q4 2022, up from 4 in Q3 2022.
  • Funds reported $1.01M of Pacer BioThreat Strategy ETF stock for Q4 2022, down 10% quarter-over-quarter.
  • 2 funds opened new Pacer BioThreat Strategy ETF positions in Q4 2022 and 0 closed out, a net change of +2 holders.
  • The largest Pacer BioThreat Strategy ETF buyer in Q4 2022 was Rockefeller Capital Management, an estimated $38.8K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q4 2022 was Royal Bank of Canada, an estimated $308K sold.

Based on aggregated 13F filings for Q4 2022.